000285160 001__ 285160
000285160 005__ 20260211160436.0
000285160 0247_ $$2doi$$a10.1001/jamanetworkopen.2025.58573
000285160 0247_ $$2pmid$$apmid:41665901
000285160 037__ $$aDZNE-2026-00182
000285160 041__ $$aEnglish
000285160 082__ $$a610
000285160 1001_ $$aHalbgebauer, Rebecca$$b0
000285160 245__ $$aBlood-Based Analysis of Different Tau Variants in Patients With Multiple Traumatic Injuries.
000285160 260__ $$aChicago, Ill.$$bAmerican Medical Association$$c2026
000285160 3367_ $$2DRIVER$$aarticle
000285160 3367_ $$2DataCite$$aOutput Types/Journal article
000285160 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770822136_28074
000285160 3367_ $$2BibTeX$$aARTICLE
000285160 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285160 3367_ $$00$$2EndNote$$aJournal Article
000285160 520__ $$aWith blood-based phosphorylated tau biomarkers soon to be used for diagnosis of Alzheimer disease, analyzing tau levels in other conditions could enhance biomarker interpretability. Moreover, mechanisms of tau release into circulation remain unclear.To evaluate concentrations of phosphorylated and nonphosphorylated tau variants in the blood of patients with multiple traumatic injuries on days 0, 1, 5, and 10 and investigate biological processes driving tau release.This multiple-trauma cohort (injury severity score, ≥18) included 45 severely injured patients with (n = 27) and without (n = 18) moderate-to-severe traumatic brain injury on emergency computed tomographic imaging. Controls consisted of 24 healthy volunteers. Participants were recruited from December 1, 2013, to October 31, 2022. Blood samples were analyzed for brain-derived tau (BD-tau), total tau (t-tau), and phosphorylated tau 217 (p-tau217) and 231 (p-tau231) levels. Associations among tau concentrations, clinical data, and outcome (eg, Glasgow Coma Scale [GCS] score) were assessed. Data were analyzed from March 1, 2023, to September 30, 2024.Serum BD-tau, t-tau, p-tau217, and p-tau231 levels.A total of 214 serum samples were analyzed. Median age of the 45 patients was 48 (IQR, 33-60) years (35 [77.8%] male); median age of the 24 controls, 43 (IQR, 28-50) years (16 [66.7%] male). Median serum levels of tau variants were increased in patients with multiple traumatic injuries at day 0 compared with controls (t-tau: 43 [IQR, 21-95] vs 3 [IQR, 3-5] pg/mL; BD-tau: 78 [IQR, 30-343] vs 2 [IQR, 2-3] pg/mL; p-tau231: 61 [IQR, 21-79] vs 2 [IQR, 1-3] pg/mL; all, P < .001). Only median BD-tau levels remained elevated until day 10 (day 1, 25 [IQR, 14-69] pg/mL; day 5, 9 [IQR, 4-15] pg/mL; day 10, 8 [IQR, 4-18] pg/mL). Median tau levels at admission were higher in patients with lower GCS scores (BD-tau: 107 [ IQR, 59-838] vs 33 [IQR, 24-78] pg/mL [P = .01]; p-tau231: 76 [IQR, 36-114] vs 28 [IQR, 9-63] pg/mL [P = .02]). Elevated median tau levels were also observed in patients with hemorrhagic shock vs those without shock (eg, BD-tau on day 0: 113 [IQR, 78-378] vs 31 [IQR, 24-61] pg/mL; P = .002) and in nonsurvivors vs survivors with uncomplicated courses (eg, BD-tau on day 1: 92 [IQR, 22-527] vs 16 [IQR, 7-23] pg/mL; P = .009).In this exploratory study among a cohort of patients with multiple traumatic injuries, levels of tau variants reflected both direct and indirect neurological injury, with BD-tau showing the most persistent elevation in the acute phase.
000285160 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285160 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285160 650_7 $$2NLM Chemicals$$atau Proteins
000285160 650_7 $$2NLM Chemicals$$aBiomarkers
000285160 650_7 $$2NLM Chemicals$$aMAPT protein, human
000285160 650_2 $$2MeSH$$aHumans
000285160 650_2 $$2MeSH$$atau Proteins: blood
000285160 650_2 $$2MeSH$$aMale
000285160 650_2 $$2MeSH$$aFemale
000285160 650_2 $$2MeSH$$aAdult
000285160 650_2 $$2MeSH$$aMiddle Aged
000285160 650_2 $$2MeSH$$aBiomarkers: blood
000285160 650_2 $$2MeSH$$aBrain Injuries, Traumatic: blood
000285160 650_2 $$2MeSH$$aPhosphorylation
000285160 650_2 $$2MeSH$$aCohort Studies
000285160 650_2 $$2MeSH$$aCase-Control Studies
000285160 7001_ $$aGonzalez-Ortiz, Fernando$$b1
000285160 7001_ $$aMayer, Benjamin$$b2
000285160 7001_ $$aBerger, Claudius$$b3
000285160 7001_ $$aBergmann, Christian$$b4
000285160 7001_ $$aRinderknecht, Helen$$b5
000285160 7001_ $$aBarth, Eberhard$$b6
000285160 7001_ $$aWohlgemuth, Lisa$$b7
000285160 7001_ $$aMannes, Marco$$b8
000285160 7001_ $$aOtto, Markus$$b9
000285160 7001_ $$0P:(DE-2719)9002007$$aTumani, Hayrettin$$b10$$udzne
000285160 7001_ $$aRelja, Borna$$b11
000285160 7001_ $$aGebhard, Florian$$b12
000285160 7001_ $$aHuber-Lang, Markus$$b13
000285160 7001_ $$aZetterberg, Henrik$$b14
000285160 7001_ $$0P:(DE-2719)9002026$$aHalbgebauer, Steffen$$b15$$udzne
000285160 7001_ $$aBlennow, Kaj$$b16
000285160 773__ $$0PERI:(DE-600)2931249-8$$a10.1001/jamanetworkopen.2025.58573$$gVol. 9, no. 2, p. e2558573 -$$n2$$pe2558573$$tJAMA network open$$v9$$x2574-3805$$y2026
000285160 8564_ $$uhttps://pub.dzne.de/record/285160/files/DZNE-2026-00182_Restricted.pdf
000285160 8564_ $$uhttps://pub.dzne.de/record/285160/files/DZNE-2026-00182_Restricted.pdf?subformat=pdfa$$xpdfa
000285160 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002007$$aExternal Institute$$b10$$kExtern
000285160 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000285160 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285160 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJAMA NETW OPEN : 2022$$d2024-12-09
000285160 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-09
000285160 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-09
000285160 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-10-18T13:36:16Z
000285160 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-10-18T13:36:16Z
000285160 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-10-18T13:36:16Z
000285160 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-09
000285160 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-09
000285160 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-09
000285160 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-09
000285160 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-09
000285160 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJAMA NETW OPEN : 2022$$d2024-12-09
000285160 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-09
000285160 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-09
000285160 9201_ $$0I:(DE-2719)5000077$$kClinical Study Center (Ulm)$$lClinical Study Center (Ulm)$$x0
000285160 980__ $$ajournal
000285160 980__ $$aEDITORS
000285160 980__ $$aVDBINPRINT
000285160 980__ $$aI:(DE-2719)5000077
000285160 980__ $$aUNRESTRICTED